Search Results
Your search for ,tWo matches 12466 pages
Showing 1651 - 1700First-Line Nivolumab/Ipilimumab Followed by Nivolumab in a Clinically Diverse Population With Unresectable Stage III or IV Melanoma
In the phase IIIb CheckMate 401 trial reported in the Journal of Clinical Oncology, Reinhard Dummer, MD, and colleagues described outcomes with first-line nivolumab/ipilimumab followed by nivolumab in a clinically diverse population of patients with unresectable stage III or IV melanoma, including...
FDA Approves Talazoparib With Enzalutamide for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
On June 20, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna) with enzalutamide for homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer. TALAPRO-2 Efficacy was evaluated in TALAPRO-2 (ClinicalTrials.gov identifier...
Adagrasib Shows Activity in Patients With KRAS G12C–Mutated NSCLC and Untreated Brain Metastases
The KRAS G12C inhibitor adagrasib may be effective at suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to a new study published by Negrao et al in the Journal of Clinical Oncology....
Older Breast Cancer Survivors May Experience Accelerated Aging, Worse Functional Outcomes Following Chemotherapy
Investigators have found that older breast cancer survivors—particularly those exposed to chemotherapy—may experience greater epigenetic aging and poorer outcomes than those without a history of cancer, according to a new study published by Rentscher et al in Cancer. Background Epigenetic aging...
VISION Trial: Health-Related Quality of Life With the Addition of Lu-177 Vipivotide Tetraxetan to Standard of Care in Patients With Advanced Prostate Cancer
In an analysis from the phase III VISION trial reported in The Lancet Oncology by Karim Fizazi, MD, PhD, and colleagues, the addition of lutetium (Lu-177) vipivotide tetraxetan to standard of care was associated with improved health-related quality of life in patients with prostate-specific...
Longitudinal ctDNA Methylation Status and Risk of Recurrence After Surgery in Patients With Stage I to III Colorectal Cancer
In a Chinese study reported in JAMA Oncology, Mo et al found that longitudinal measurement of circulating tumor DNA (ctDNA) methylation permitted early detection of disease recurrence in patients undergoing surgery for stage I to III colorectal cancer. Study Details In the prospective cohort...
FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed or Refractory DLBCL
On June 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma,...
Alectinib May Be More Effective When Taken With Larger Meals in Some Patients With NSCLC
Researchers have found that when the small molecule kinase inhibitor alectinib was taken in combination with a fuller breakfast or lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast in patients with non–small cell lung cancer (NSCLC), according...
S-1 Chemoradiotherapy for Older Patients With Inoperable Esophageal Squamous Cell Carcinoma
In a Chinese phase III trial reported in JAMA Network Open, Wang et al found that oral S-1 chemotherapy given with simultaneous integrated boost radiotherapy (SIB-RT) and following SIB-RT improved overall survival in patients aged 70 or older with inoperable esophageal squamous cell carcinoma....
Adagrasib in Treatment of KRAS G12C–Mutated Advanced Solid Tumors
As reported in the Journal of Clinical Oncology by Tanios S. Bekaii-Saab, MD, and colleagues, findings in the phase II cohort of the KRYSTAL-1 trial showed activity of adagrasib in patients with KRAS G12C–mutated advanced solid tumors. As noted by the investigators, the KRAS G12C inhibitor...
Personalized mRNA Vaccines May Transform the Treatment of Melanoma
The rates of survival and disease recurrence improved significantly when a personalized mRNA vaccine tailored to the patients’ tumor genetics was coupled with immunotherapy in those who had undergone surgery for high-risk melanoma, according to novel findings presented by Khattak et al at the 2023...
Exposure to Ultraviolet Radiation May Propel Transformation of BPDCN Cells to Leukemia in the Skin
For some precancerous cells, traveling from the bone marrow to the skin can trigger genetic transformations that can result in leukemia, according to a novel study published by Griffin et al in Nature. The new findings may have shed light on what researchers have termed the “genetic travelogue” of...
Factors Associated With Nonadherence to Lung Cancer Screening Recommendations
In a single-institution retrospective cohort study reported in JAMA Network Open, Lin et al identified factors associated with nonadherence to lung cancer screening recommendations among patients undergoing screening—and found that negative findings on two successive screenings were associated with ...
Fecal Microbiota Transplantation: Its Role for Patients Undergoing Allogeneic HCT and Receiving Induction Therapy for AML
In a single-institution phase II study reported in the Journal of Clinical Oncology, Rashidi et al found that fecal microbiota transplantation (FMT) did not reduce the risk of infection in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) or patients with acute myeloid...
Study Finds Preoperative MRI Does Not Significantly Impact Margin Status in Patients With Breast Cancer
The use of preoperative magnetic resonance imaging (MRI) did not significantly reduce positive margins after breast-conserving surgery, according to data presented during a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Although MRI has been shown to detect...
NCI’s ComboMATCH Initiative Will Evaluate New Drug Combinations Guided by Tumor Biology
The National Cancer Institute (NCI) has launched a new set of large, precision medicine–based clinical trials—known as the ComboMATCH initiative—that will examine the efficacy of novel drug combinations targeting specific tumor mutations in adult and pediatric patients with cancer. The new...
Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Platinum-Resistant or Platinum-Refractory Ovarian Cancer
In the phase II VIRO-15 trial reported in JAMA Oncology, Holloway et al found that virotherapy with the modified oncolytic vaccinia virus olvimulogene nanivacirepvec plus platinum-based chemotherapy with or without bevacizumab showed activity in patients with platinum-resistant or...
Polatuzumab Vedotin-piiq for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, 2023, polatuzumab vedotin-piiq was approved for use with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with diffuse large B-cell lymphoma (DLBCL)–not otherwise specified or those with high-grade B-cell lymphoma who have an International...
ASCO Updates Guideline for Management of Anxiety and Depression in Adult Cancer Survivors
Cancer takes a significant psychological toll on affected individuals. Cancer survivors have a significantly elevated risk of developing a mental health disorder compared with the general population, yet their psychological symptoms are often underrecognized and undertreated. To help equip...
Expert Point of View: Matteo Lambertini, MD, PhD
Invited discussant of these two trials, Matteo Lambertini, MD, PhD, Associate Professor at the University of Genova–IRCCS Policlinico San Martino Hospital Genoa, Italy, emphasized the importance of longer follow-up periods for both these clinical trials and the need to wait for the additional...
Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers
Immunotherapy regimens involving the PD-L1 monoclonal antibody atezolizumab have demonstrated promising results in patients with early-stage, triple-negative breast cancer and HER2-positive breast cancer, according to a pair of studies presented at the European Society for Medical Oncology (ESMO)...
Expert Point of View: Tina Cascone, MD, PhD
Discussant of the Neotorch study abstract, Tina Cascone, MD, PhD, of the Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, commended the authors for completing the initial analysis of the phase III randomized Neotorch trial, which...
Endocrine Therapy Switch With or Without Ribociclib After Disease Progression on Endocrine Therapy and CDK4/6 Inhibition for Metastatic Breast Cancer
In the phase II MAINTAIN trial reported in the Journal of Clinical Oncology, Kevin Kalinsky, MD, MS, and colleagues found that a switch in endocrine therapy plus continued CDK4/6 inhibitor treatment with ribociclib was associated with improved progression-free survival in patients with hormone...
5α-Reductase Inhibitor Use and Progression of Bladder Cancer in South Korean Males
In a Korean cohort study reported in JAMA Network Open, An et al found that men with prescriptions for 5α-reductase inhibitors prior to diagnosis of urothelial bladder cancer had better outcomes than those with no prior prescriptions. Study Details The study analyzed patient claims data from the...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal cancer,...
Stopping Immunotherapy After 2 Years vs Continuing Treatment May Yield Similar Survival Outcomes in Patients With Advanced NSCLC
Patients with advanced non–small cell lung cancer (NSCLC) may be able to stop receiving immunotherapy at 2 years as long as their cancer hasn’t progressed, according to new findings presented by Sun et al at the 2023 ASCO Annual Meeting (Abstract 9101) and simultaneously published in JAMA Oncology. ...
Race and Ethnicity May Affect 21-Gene Recurrence Score in Patients With Estrogen Receptor–Positive Breast Cancer
Investigators have found that race and ethnicity may affect the 21-gene recurrence score in patients with early-stage, estrogen receptor–positive breast cancer, according to new findings presented by Gill et al at the 2023 ASCO Annual Meeting (Abstract 511). Background The 21-gene recurrence...
Exercise May Strengthen Immune System in Patients With Multiple Myeloma
Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....
Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel when compared to the current standard-of-care chemoimmunotherapy, according to results of the...
Erdafitinib Achieves Responses Across Multiple Cancer Types With FGFR Alterations
Three clinical trials demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations. The data were presented at the 2023 ASCO Annual Meeting. Erdafitinib is an oral medication that blocks the activity of FGFR signaling...
Ciltacabtagene Autoleucel Reduces Risk of Disease Progression in Patients With Lenalidomide-Refractory Multiple Myeloma
Ciltacabtagene autoleucel, a B-cell maturation antigen–targeting chimeric antigen receptor (CAR) T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among patients with lenalidomide-refractory disease. Results from the...
Chemotherapy-Induced Peripheral Neuropathy May Be More Severe With Paclitaxel Than With Docetaxel
Researchers have found that patients who have breast cancer who undergo treatment with taxanes show a pattern of clinically meaningful, persistent sensory and motor symptoms associated with chemotherapy-induced peripheral neuropathy, according to new findings presented by Trivedi et al at the 2023...
Radiation May Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy may safely forgo radiation therapy before surgery, based on the findings of the PROSPECT trial. These data were presented by Deborah Schrag, MD, FASCO, MPH, at the 2023 ASCO Annual Meeting (Abstract LBA2) and...
Adjuvant Osimertinib Improves Survival in Patients With Resected EGFR-Mutated NSCLC
Treatment with osimertinib after surgery significantly lowered the risk of death in adults with completely resected EGFR-mutated stage IB, II, or IIIA non–small cell lung cancer (NSCLC), according to the findings of the international ADAURA study. The research was presented at the 2023 ASCO Annual...
Patients With SLFN11-Expressing SCLC May Benefit From Immune Checkpoint Inhibitor Plus PARP Inhibitor
Among patients with extensive-stage small cell lung cancer (SCLC) positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance treatment with the immune checkpoint inhibitor atezolizumab plus the PARP inhibitor talazoparib had significantly longer progression-free...
Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab,...
Veterans Exposed to Agent Orange May Be at Increased Risk of Developing Myeloproliferative Neoplasms
A population-based study using information from a database of veterans found that those who had been exposed to Agent Orange may be at an increased risk of developing myeloproliferative neoplasms (MPNs). Agent Orange is a herbicide that was used by the U.S. military in Korea and Vietnam to clear...
Early Cessation of Neoadjuvant Chemotherapy May Lead to Worse Outcomes in Patients With Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to cystectomy may have an increased risk of cancer recurrence and worse survival outcomes, according to the findings of a retrospective study presented by Chakraborty et al at the 2023 ASCO Annual ...
Zanidatamab Shows Activity in Refractory HER2-Amplified Biliary Tract Cancer
The HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer, according to research presented by Shubham Pant, MD, and colleagues at the 2023 ASCO Annual Meeting (Abstract 4008). The results were also...
Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer
Patients with newly diagnosed advanced ovarian cancer without a BRCA mutation who received durvalumab and olaparib in addition to the standard of care had improved progression-free survival compared with those who received the standard of care alone, according to the interim analysis of DUO-O, an...
Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer
Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from the large, international phase III SHAPE clinical trial. The research was presented by Plante...
Extended Lymphadenectomy May Not Benefit Patients With Clinically Localized Muscle-Invasive Bladder Cancer
Extended lymphadenectomy in patients undergoing radical cystectomy for clinically localized muscle-invasive bladder cancer was not associated with improved disease-free survival or overall survival and may increase the risk of adverse events and postsurgical mortality, according to new findings...
Study Finds Wide Variations in Intratumoral Microbiome of Patients With Early- vs Late-Onset Colorectal Cancer
Researchers have found that the bacteria, fungi, and viruses within the tumors of patients with colorectal cancer varied significantly depending on whether they were diagnosed with early-onset or late-onset disease, according to new findings presented by Weinberg et al at the 2023 ASCO Annual...
ATOM Coalition Seeks to Ensure Equitable Cancer Care in Low- and Middle-Income Countries
A new global health initiative, the Access to Oncology Medicines (ATOM) Coalition, may be capable of reducing the burden of suffering and death from cancer in low- and middle-income countries by improving patient access to essential cancer medicine. Gilberto Lopes, MD, FASCO, MBA, will highlight...
FDA Approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 31, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers
In a small study reported in JAMA Network Open, D’Andrea et al found that diffusing alpha-emitter radiation therapy—a novel solid tumor management strategy using alpha-particle interstitial brachytherapy—appeared to be safe and showed activity in patients with recurrent or unresectable skin...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
An Oncology Leader Whose Immigrant Parents Taught Him by Example About Life and Service to Humanity
According to Sunil R. Hingorani, MD, PhD, his parents figured heavily on who he became as a person and on his career choices, which ultimately led to his current position as Director of the Pancreatic Cancer Center of Excellence at the University of Nebraska College of Medicine, Omaha. “My father...
Involvement in SWOG and JCO Leads to a Fulfilling Career as a Leader in Oncology
Jonathan W. Friedberg, MD, MMSc, Director of the James P. Wilmot Cancer Institute, grew up in a suburb of Milwaukee. While his school friends were attending camp, he spent his summers working on the family farm. “Perhaps the hardest work I’ve ever done was haying on a hot, humid night in July,...
